In parallel, Yashiro et al. studied the efficacy of the c-Met inhibitor SU11274 in combination with irinotecan and found that they have superior efficacy in suppressing in vivo tumor growth by SP-enriched cell lines (OCUM-2M/SP cells) than either group monotherapy [66]. Here, MET is linked to neoplasm.